{"drugs":["Regorafenib","Stivarga"],"mono":{"0":{"id":"930293-s-0","title":"Generic Names","mono":"Regorafenib"},"1":{"id":"930293-s-1","title":"Dosing and Indications","sub":[{"id":"930293-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Gastrointestinal stromal tumor, Locally advanced, unresectable, or metastatic disease, after treatment with imatinib and sunitinib:<\/b> 160 mg ORALLY once daily with a low-fat breakfast on days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity<\/li><li><b>Metastatic colorectal cancer, In patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, and anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy:<\/b> 160 mg ORALLY once daily with a low-fat breakfast on days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity<\/li><\/ul>"},{"id":"930293-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatric patients have not been established "},{"id":"930293-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>any grade 3 or 4 adverse reaction (other than hepatotoxicity):<\/b> withhold until recovery and resume at reduced dose of 120 mg daily; for any grade 3 or 4 adverse reaction occurring on 120 mg daily, withhold until recovery and resume at a reduced dose of 80 mg daily; for failure to tolerate 80 mg daily, discontinue; for any grade 4 adverse reaction at any time, resume therapy only if potential benefit outweighs the risks<\/li><li><b>hand-foot skin reaction:<\/b> for grade 3, interrupt therapy for at least 7 days; for first occurrence, grade 2, and of any duration, withhold until recovery and resume at reduced dose of 120 mg daily; for grade 2, recurrent or not improved within 7 days despite initial dose reduction, withhold until recovery and resume at reduced dose of 80 mg daily; for failure to tolerate 80 mg daily, discontinue<\/li><li><b>hepatic impairment:<\/b> no adjustment required in patients with mild or moderate impairment; use not recommended in patients with severe impairment (Child-Pugh class C)<\/li><li><b>hepatic toxicity:<\/b> for grade 3 elevation of AST\/ALT, resume at reduced dose of 120 mg daily only if potential benefit outweighs the risk; for any occurrence of AST or ALT more than 20 x ULN, discontinue; for any occurrence of AST or ALT more than 3 x ULN with concurrent bilirubin more than 2 x ULN, discontinue; for any recurrence of AST or ALT more than 5 x ULN despite initial dose reduction to 120 mg daily, discontinue<\/li><li><b>hypertension:<\/b> for symptomatic grade 2 hypertension, withhold therapy until blood pressure is adequately controlled; for severe or uncontrolled hypertension, discontinue<\/li><li><b>renal impairment, mild:<\/b> no dosage adjustment required<\/li><\/ul>"},{"id":"930293-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Gastrointestinal stromal tumor, Locally advanced, unresectable, or metastatic disease, after treatment with imatinib and sunitinib<\/li><li>Metastatic colorectal cancer, In patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, and anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy<\/li><\/ul>"}]},"2":{"id":"930293-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Severe and sometimes fatal hepatotoxicity has been observed with regorafenib therapy. Monitor hepatic function prior to and during therapy. Adjust, interrupt, or discontinue dose if hepatoxicity occurs.<br\/>"},"3":{"id":"930293-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930293-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930293-s-3-10","title":"Precautions","mono":"<ul><li>hepatotoxicity, severe and sometimes fatal, has been reported; monitoring recommended; dose reduction, interruption, or discontinuation may be required<\/li><li>cardiac ischemia and infarction have been reported; discontinue for new or acute onset ischemia or infarction and resume after resolution of ischemic events if benefits outweigh risks<\/li><li>concomitant use with strong CYP3A4 inducers (eg, rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) should be avoided<\/li><li>concomitant use with strong CYP3A4 inhibitors (eg, clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole) should be avoided<\/li><li>dermatologic reaction, hand-foot skin reaction and rash, have been reported; interrupt and reduce dose or discontinue depending on severity and\/or persistence<\/li><li>gastrointestinal perforation or fistulae have been reported; permanently discontinue<\/li><li>hemorrhage, including fatal hemorrhages of the respiratory, gastrointestinal, or genitourinary tracts, has been reported; permanently discontinue for severe or life-threatening hemorrhage<\/li><li>hepatic impairment, severe (Child-Pugh Class C); use not recommended<\/li><li>hypertension, including hypertensive crisis, has been reported; monitoring recommended; interrupt or discontinue for severe or uncontrolled hypertension<\/li><li>pregnancy; may cause fetal harm<\/li><li>Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been reported; discontinue if confirmed RPLS develops<\/li><li>wound dehiscence may occur; discontinue<\/li><li>wound healing complications may occur; discontinue before surgery and reconsider resuming if wound healing adequate<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930293-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"930293-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930293-s-4","title":"Drug Interactions","sub":[{"id":"930293-s-4-13","title":"Contraindicated","mono":"<ul>Eletriptan (theoretical)<\/ul>"},{"id":"930293-s-4-14","title":"Major","mono":"<ul><li>Amiodarone (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clozapine (established)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (established)<\/li><li>Lopinavir (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Ospemifene (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"930293-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, All grades (30% to 59%)<\/li><li><b>Dermatologic:<\/b>Acral erythema, All grades (45% to 67%)<\/li><li><b>Endocrine metabolic:<\/b>Hypocalcemia (17% to 59%), Hyponatremia (30%), Hypophosphatemia (55% to 57%), Weight loss (14% to 32%)<\/li><li><b>Gastrointestinal:<\/b>Decrease in appetite (31% to 47%), Diarrhea (43% to 47%), Inflammatory disease of mucous membrane (33% to 40%), Nausea (20%), Vomiting (17%)<\/li><li><b>Hematologic:<\/b>Anemia (79%), Lymphocytopenia (30% to 54%), Thrombocytopenia (13% to 41%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, All grades (39% to 45%), AST\/SGOT level raised, All grades (58% to 65%), Hyperbilirubinemia (33% to 45%), Increased serum lipase level (14% to 46%)<\/li><li><b>Neurologic:<\/b>Asthenia, Difficulty speaking (30% to 39%)<\/li><li><b>Renal:<\/b>Proteinuria (33% to 60%)<\/li><li><b>Other:<\/b>Fatigue, Fever (21% to 28%), Infectious disease (31% to 32%), Pain (29%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Grade 3 or 4 (8% to 28%), Hypertensive crisis (0.25%), Myocardial infarction, Myocardial ischemia<\/li><li><b>Dermatologic:<\/b>Acral erythema, Grade 3 or 4 (17% to 22%), Erythema multiforme (0.2%), Stevens-Johnson syndrome (0.2%), Toxic epidermal necrolysis (0.17%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal fistula, Gastrointestinal perforation<\/li><li><b>Hematologic:<\/b>Hemorrhage (11% to 21%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, Grades 3 and 4 (grade 3, 4% to 5%; grade 4, 1%), AST\/SGOT level raised, Grades 3 and 4 (grade 3, 3% to 5%; grade 4, 1%), Hepatotoxicity, Liver failure (0.8% to 1.6%)<\/li><\/ul>"},"6":{"id":"930293-s-6","title":"Drug Name Info","sub":{"0":{"id":"930293-s-6-17","title":"US Trade Names","mono":"Stivarga<br\/>"},"3":{"id":"930293-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930293-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930293-s-7","title":"Mechanism Of Action","mono":"Regorafenib is an oral kinase inhibitor acting on various membrane-bound and intracellular kinases involved in cellular functions and processes, including oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.<br\/>"},"8":{"id":"930293-s-8","title":"Pharmacokinetics","sub":[{"id":"930293-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 4 hours<\/li><li>Bioavailability, Oral tablet: 69%<\/li><li>Effect of food: Increased AUC of parent and active metabolites (low-fat meal); Increased AUC of parent and decreased AUC of active metabolites (high-fat meal)<\/li><\/ul>"},{"id":"930293-s-8-24","title":"Distribution","mono":"Plasma proteins: 99.5% <br\/>"},{"id":"930293-s-8-25","title":"Metabolism","mono":"<ul><li>Metabolized by CYP3A4 and UGT1A9<\/li><li>M-2 (N-oxide-regorafenib): active<\/li><li>M-5 (N-oxide- and N-desmethyl-regorafenib): active<\/li><\/ul>"},{"id":"930293-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 47% unchanged, 24% changed<\/li><li>Renal: 19%<\/li><\/ul>"},{"id":"930293-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Regorafenib: 28 hours<\/li><li>M-2: 25 hours<\/li><li>M-5: 51 hours<\/li><\/ul>"}]},"9":{"id":"930293-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Store the tablets in the original bottle; once opened, use within 7 weeks.<\/li><li>Take the tablet at same time every day, after a low-fat meal containing less than 600 calories and less than 30% fat.<\/li><li>Swallow the tablet whole with water.<\/li><\/ul>"},"10":{"id":"930293-s-10","title":"Monitoring","mono":"<ul><li>evidence of tumor response indicates efficacy<\/li><li>liver function tests (AST, ALT, bilirubin); before drug initiation and at least every 2 weeks during the first 2 months of therapy, with at least monthly assessments thereafter or as clinically warranted; weekly assessments required with test elevations until levels fall to less than 3 times the ULN or baseline<\/li><li>blood pressure; weekly for the first 6 weeks of treatment, then every treatment cycle or more often as clinically indicated<\/li><li>signs of hepatic adverse events; in patients with hepatic impairment<\/li><\/ul>"},"11":{"id":"930293-s-11","title":"How Supplied","mono":"<b>Stivarga<\/b><br\/>Oral Tablet: 40 MG<br\/>"},"13":{"id":"930293-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report symptoms of hepatotoxicity, myocardial infarction, or myocardial ischemia.<\/li><li>Counsel patient to report symptoms of severe hypertension or reversible posterior leukoencephalopathy syndrome.<\/li><li>Instruct patient to report symptoms of hemorrhage, gastrointestinal perforation, or fistula.<\/li><li>Tell patient to report any dermatologic reactions.<\/li><li>Recommend female patient avoid pregnancy during and for up to 2 months after therapy.<\/li><li>Warn male patient to prevent pregnancy in sexual partner during and for up to 2 months after therapy.<\/li><li>Side effects may include anorexia, diarrhea, abdominal pain, nausea, mucositis, fever, weight loss, asthenia, fatigue, and dysphonia.<\/li><li>Tell patient to take drug at the same time each day after a low-fat meal (less than 600 calories; less than 30% fat).<\/li><li>Instruct patient to take a missed dose as soon as possible on the same day it was scheduled, otherwise skip the missed dose.<\/li><\/ul>"}}}